Albert Oliver-Gris

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

The versatile interplay between steatotic liver disease and liver cancer.

The versatile interplay between steatotic liver disease and liver cancer.

Journal: Nature reviews. Cancer

Published: February 24, 2026

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma.

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma.

Journal: Cell reports. Medicine

Published: July 27, 2025

Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma.

Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma.

Journal: JHEP reports : innovation in hepatology

Published: June 06, 2025

Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib.

Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib.

Journal: Molecular oncology

Published: May 29, 2025

E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.

E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 25, 2025

Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.

Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.

Journal: JHEP reports : innovation in hepatology

Published: April 05, 2024

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Journal: Journal of hepatology

Published: February 02, 2024

Activated ATF6α is a hepatic tumour driver restricting immunosurveillance.

Activated ATF6α is a hepatic tumour driver restricting immunosurveillance.

Journal: Nature

Published: October 05, 2023

Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling.

Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling.

Journal: Nature genetics

Published: August 16, 2023

Human-correlated genetic models identify precision therapy for liver cancer.

Human-correlated genetic models identify precision therapy for liver cancer.

Journal: Nature

Published: May 09, 2022

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.

Journal: Oncogene

Published: May 03, 2022

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells.

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells.

Journal: Cancers

Published: April 15, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026